YouTubeFeed

The dawn of surgery bots + buy a home for $250 (w/ Andromeda & Mogul) | E2313

Summary

This “founder double feature” episode of This Week in Startups is hosted solo by co-host Alex Wilhelm (Jason Calacanis appears throughout as a second questioner, but this is not a Jason-and-Lon episode). The first half features Nick Damiano, CEO and co-founder of Andromeda Surgical, which is building the software “autonomy layer” for robotic surgery rather than new hardware — it runs its iPad-controlled robot on an off-the-shelf arm from the German manufacturer KUKA. Andromeda is starting with HoLEP, a urology procedure for enlarged prostates, and has built early autonomy features including a “Google Maps for the body” spatial-tracking system and auto-pivoting force control. Damiano argues the company’s real moat is proprietary surgical data — with only 45 completed cases, Andromeda holds what he calls “100% of the world’s data” on robot kinematics for this procedure. The long-term vision is a “super surgeon” model where one human oversees many simultaneous procedures like an air-traffic controller, and the company has already raised a “tens of millions” round after spending roughly $15 million to go from zero to a launched robot in three years — a fraction of typical MedTech spend.

The second half shifts to Alex Blackwood, founder and CEO of Mogul, which lets everyday investors buy fractional shares of single-family rental homes for as little as $250. Blackwood, a Goldman Sachs real-estate-private-equity alum, explains how Mogul has fully diligenced and structured 130 properties (600+ units) with 20-80 investors per deal, handles all property management behind the scenes (repairs under $1,000 are automatic; above that triggers an investor governance vote), and capitalizes maintenance and vacancy reserves upfront so investors are never hit with a surprise capital call. He details Mogul’s three revenue streams — a 5% buyer-side platform fee, a 1.5-2% seller-side fee, and interest on reserves — and previews a planned secondary market where Mogul itself acts as day-one market maker for liquidity in an asset class that’s traditionally illiquid.

A note on speaker attribution: the interview-transcriber’s automated diarization for this episode was significantly broken and required manual, context-based reconstruction. Two problems compounded: (1) the transcriber only knew the seeded name “Alex Blackwood” and had no hint that a second, different “Alex” — co-host Alex Wilhelm — was present, so it labeled every host line in the first half as “Alex Blackwood”; and (2) several mid-answer segments were split across the tool’s 3-minute transcription chunk boundaries and misattributed to the wrong person entirely (e.g., lines where Nick Damiano says “we built,” “my co-founder,” or cites specific data about Andromeda were originally tagged as the host). Every speaker label in this file has been reconstructed from conversational context (who is asking a question vs. describing their own company in the first person) rather than taken as-is from the raw JSON. Timestamps are unaffected and still trace directly to the JSON’s segment timestamps.

Highlights

”Google Maps for the body”

Nick Damiano explains Andromeda's spatial tracking system

“One is like Google Maps for the body where it tracks the landmarks and what you’ve done in the surgery so far in real time throughout the procedure so you always have that spatial sense and just know where you are and what you need to do next.” — Nick Damiano, 5:06

Clip command
yt-dlp --download-sections "*5:06-6:00" "https://www.youtube.com/watch?v=FWc9NptoNP0" --force-keyframes-at-cuts --merge-output-format mp4 -o "google-maps-for-the-body.mp4"

”That’s 100% of the world’s data”

Nick Damiano on Andromeda's proprietary surgical dataset

“Right now we’ve done, I think, the only, we’ve done 45 cases and it’s the only data set of 45 cases that exists. Like that’s 100% of the world’s data, and it’s really hard for anyone else to get that.” — Nick Damiano, 7:02

Clip command
yt-dlp --download-sections "*7:02-7:47" "https://www.youtube.com/watch?v=FWc9NptoNP0" --force-keyframes-at-cuts --merge-output-format mp4 -o "hundred-percent-of-worlds-data.mp4"

”A surgeon sitting at an air traffic control center”

Nick Damiano describes the super surgeon vision

“So what we envision in the long term is a surgeon sitting at kind of an air traffic control center where there’s a lot of different procedures happening. They can orchestrate that at a high level but not have to do all the tedious mundane tasks all the time. So maybe you’re overseeing 10 surgeries instead of one right now.” — Nick Damiano, 14:16

Clip command
yt-dlp --download-sections "*14:16-15:10" "https://www.youtube.com/watch?v=FWc9NptoNP0" --force-keyframes-at-cuts --merge-output-format mp4 -o "super-surgeon-air-traffic-control.mp4"

”$15 million total, whereas the norm is hundreds of millions”

Nick Damiano on Andromeda's capital efficiency

“We were the fastest robot from zero to launch in three years and we’ve only spent about 15 million total in getting there, whereas the norm is hundreds of millions.” — Nick Damiano, 22:51

Clip command
yt-dlp --download-sections "*22:51-23:30" "https://www.youtube.com/watch?v=FWc9NptoNP0" --force-keyframes-at-cuts --merge-output-format mp4 -o "fifteen-million-vs-hundreds-of-millions.mp4"

”Completely headache-free” real estate

Alex Blackwood explains Mogul's hands-off property management

“There’s that old quote from Carnegie: 90% of millionaires became such through real estate investing. However, the headaches attributed to real estate are tremendous, right? You’ve all heard the horror stories of the 3:00 a.m. tenant coming to you because the sink is burst.” — Alex Blackwood, 33:30

Clip command
yt-dlp --download-sections "*33:30-34:25" "https://www.youtube.com/watch?v=FWc9NptoNP0" --force-keyframes-at-cuts --merge-output-format mp4 -o "headache-free-real-estate.mp4"

”The IRS wrote the tax code to incentivize two things”

Alex Blackwood on real estate depreciation tax benefits

“We like to joke that the IRS wrote the tax code to incentivize two things: procreation and homeownership. We can’t help with the first, but we sure as hell can help with that second.” — Alex Blackwood, 37:43

Clip command
yt-dlp --download-sections "*37:43-38:13" "https://www.youtube.com/watch?v=FWc9NptoNP0" --force-keyframes-at-cuts --merge-output-format mp4 -o "irs-tax-code-joke.mp4"

Key Points

  • Andromeda controls a surgical robot from an iPad (0:42) - Host Alex Wilhelm introduces Nick Damiano, CEO and co-founder of Andromeda Surgical.
  • Off-the-shelf KUKA arm, software-first strategy (3:00) - Andromeda deliberately avoids building custom hardware, focusing all effort on the autonomy software layer.
  • Starting wedge: HoLEP, a common prostate procedure (3:12) - Urologists were early robot adopters, and HoLEP has a huge skill gap between novice and expert surgeons that autonomy can close.
  • “Google Maps for the body” spatial tracking (5:06) - Real-time landmark tracking plus auto-pivoting force control to minimize tissue damage; new features ship weekly.
  • Surgical data is the real moat (7:02) - With only 45 completed cases, Andromeda holds “100% of the world’s data” on the robot kinematics for this procedure.
  • Surgical tasks generalize across body parts (9:03) - Because the set of surgical tasks is finite, autonomy built for one procedure (e.g., prostate) can transfer to others (e.g., gallbladder, eye).
  • The “super surgeon” vision: air-traffic-control surgery (14:16) - Long-term goal is one surgeon overseeing ~10 simultaneous procedures at a high level instead of performing each by hand.
  • Iteration cycle compressed from years to weeks (15:58) - Andromeda cycles cadaver-lab testing and live clinical cases in under a month, versus the MedTech industry’s typical multi-year cycles.
  • Capital efficiency: $15M to launch vs. hundreds of millions industry-wide (22:51) - Andromeda just closed a “tens of millions” round after spending ~$15M to go from zero to a launched robot in three years.
  • Cleared only in New Zealand so far (24:51) - Andromeda has LOIs signed but is currently regulatory-cleared to operate in New Zealand, with a few other countries close behind.
  • FDA path: small, frequent increments (25:26) - Nick argues nothing structurally blocks U.S. deployment as long as risk analysis and quality systems are built the right way, submitted in small increments.
  • Vision: remote surgery via Starlink-connected clinics (26:12) - A single expert surgeon could eventually oversee procedures at facilities anywhere in the world, closing the healthcare access gap.
  • Mogul: fractional single-family rental investing from $250 (29:24) - Alex Blackwood, CEO of Mogul, pitches buying shares in vetted rental homes instead of needing to buy a whole property.
  • 130 properties, 600+ units, 20-80 investors per deal (31:21) - Blackwood and his co-founder previously grew Goldman Sachs’ single-family rental platform from zero to $1B in 12 months.
  • Headache-free property management with a governance threshold (33:30) - Repairs under $1,000 are handled automatically by property managers; above that triggers an investor vote.
  • Maintenance and vacancy reserves capitalized upfront (33:30) - Mogul funds a 12-month vacancy reserve and HVAC-replacement-style maintenance reserve at purchase so investors are never hit with surprise capital calls.
  • Depreciation makes rental income largely tax-free (38:13) - The “ghost expense” of depreciation offsets the 8-12% dividend yield for income-reporting purposes.
  • Mogul’s three revenue streams (39:01) - A 5% buyer-side platform fee, a 1.5-2% seller-side fee at closing, and interest earned on maintenance/vacancy reserves.
  • Planned secondary market with Mogul as day-one market maker (42:26) - Blackwood, a former Goldman market-making analyst, wants to make the historically illiquid rental-home asset class fully liquid.
  • Picking markets: supply vs. demand dislocation (44:56) - Mogul builds a market thesis around net-new supply, rent-to-price ratios, and target price range before sourcing deals, citing Austin as a current example.

Mentions

Companies

  • Andromeda Surgical (0:42) - Nick Damiano’s autonomous-surgery startup; website andromeda-surgical.com.
  • KUKA (11:41) - German manufacturer of the off-the-shelf robotic arm Andromeda uses.
  • Intuitive Surgical (da Vinci) (4:08) - Cited as the incumbent robotic-surgery player that also started in urology.
  • Neuralink (23:30) - Andromeda has looked at hiring from Neuralink for its culture fit as a deep-tech, unconventional medical team.
  • Waymo / Tesla / Waabi / Wayve (2:02) - Referenced repeatedly as the autonomous-driving analogy for where surgical autonomy is headed.
  • Northwest Registered Agent (9:32) - Show sponsor; Delaware C Corp formation service.
  • CLA (20:05) - Show sponsor; accounting and wealth advisory, pitched via Stephen Estes.
  • MongoDB (30:23) - Show sponsor, pitched during the transition into the Mogul interview.
  • Mogul (28:43) - Alex Blackwood’s fractional single-family-rental investing platform; mogul.club.
  • Goldman Sachs (31:21) - Former employer of Blackwood and his co-founder, where they built Goldman’s single-family rental platform.
  • AngelList / The Syndicate (28:43) - Jason cites AngelList’s SPV model and thesyndicate.com as the precedent for pooled-investment structures like Mogul.
  • PadSplit (33:30) - Rental listing platform Mogul uses for algorithmic pricing alongside Airbnb.

Products & Technologies

  • HoLEP procedure (3:12) - Andromeda’s initial target surgery, a treatment for enlarged prostate (BPH).
  • iPad-controlled robotic arm (0:42) - Andromeda’s core product: an off-the-shelf robot arm operated via iPad by a surgeon.
  • “Google Maps for the body” (5:06) - Andromeda’s real-time spatial landmark-tracking feature.
  • Auto-pivoting force control (5:06) - Automatically minimizes tissue-damaging force during procedures.
  • Synthetic data / world models (17:53) - Andromeda is open to but not yet using synthetic data generation for training.
  • mogul.club (45:58) - Mogul’s investment platform for fractional rental home shares.

People

  • Nick Damiano (0:42) - Guest; CEO and co-founder of Andromeda Surgical.
  • Alex Blackwood (28:43) - Guest; founder and CEO of Mogul, former Goldman Sachs real-estate private equity and investment-banking market-making.
  • Alex Wilhelm (0:42) - Co-host for this episode; conducts the entire Andromeda Surgical interview solo before Jason takes over questioning duties partway through.
  • Jason Calacanis (0:00) - Host; asks the bulk of the questions in both segments and delivers the CLA and MongoDB ad reads.
  • Stephen Estes (20:05) - CLA advisor referenced during the sponsor segment on startup cash efficiency.

Surprising Quotes

“Right now we’ve done, I think, the only, we’ve done 45 cases and it’s the only data set of 45 cases that exists. Like that’s 100% of the world’s data, and it’s really hard for anyone else to get that.” — Nick Damiano, 7:02

“It’s tens.” / “There we go, it’s between zero and 99 million everybody, breaking news.” — Nick Damiano and Jason Calacanis, 22:46

“That’s one of the things I think is the most exciting about the long-term potential of this is that anywhere you want to be delivering healthcare, any facility around the world, even on other planets eventually…” — Nick Damiano, 26:49

“We like to joke that the IRS wrote the tax code to incentivize two things: procreation and homeownership. We can’t help with the first, but we sure as hell can help with that second.” — Alex Blackwood, 37:43

“The person on the other end of the transaction isn’t actually a person at all, it’s an institution. That institution is buying it, repackaging it, maybe selling as part of an S&P 500 ETF…” — Alex Blackwood, 42:26

Transcript

Jason Calacanis: 0:00 Syndicate, something that’s worked incredibly well, allowing a group of people to act as one unit to buy an asset. People want to buy into single family rental properties.

Nick Damiano: 0:10 Real estate as we know is the world’s largest wealth generator. 90% of millionaires became so through real estate investment. The idea is buying shares in a single family rental home because it’s completely headache-free.

Jason Calacanis: 0:22 What is the goal of your investors? They want to get 10, 15% back every year in a dividend or they want to get the appreciation?

Nick Damiano: 0:30 The assets typically yield between 8 to 12% per year for dividend payouts. That’s dollars that you can withdraw tomorrow.

Jason Calacanis: 0:37 How do you make money?

Nick Damiano: 0:40 How do we at Mogul make money you mean?

Alex Wilhelm: 0:42 Hello and welcome back to TWIST, this is Alex. Now, have you read the books in the Expanse series or seen the show? One of my favorite parts of it is whenever they get hurt, they get shot, they get irradiated, whatever it is, they go back to their ship and they put their hand and arm into a little device and it fixes them. I’ve always thought that was a beautiful vision of the future. No matter what’s wrong with you, there’s this machine that can put you back together again. Now, we’re a long way from that today, if you go into the doctor today, it’s a person, if you get some surgery done, probably also a person, and on down the healthcare chain. But there are companies right now working on building us towards a more robotic and more autonomous healthcare future, including in the realm of surgery. Now, that will either delight you or terrify you, but I wanted to learn more about where the technology is today and how quickly it’s advancing, so please join me in welcoming to the show, it’s Nick Damiano, the CEO and co-founder of Andromeda Surgical. Nick, how are you?

Nick Damiano: 1:30 Doing well. Great to be here.

Alex Wilhelm: 1:31 I forgot to ask before we started. Are you a science fiction fan?

Nick Damiano: 1:34 I am.

Alex Wilhelm: 1:35 That intro was perfect for you. Let’s, let’s start by defining where the company is going. You said on LinkedIn that quote, “surgery is currently almost untouched by AI, but in 10 years, AI and autonomy will be ubiquitous.” So paint that picture for me, where are we going to be in a decade? And then I want to go back to where we are now.

Nick Damiano: 2:02 Yeah, I mean, like a lot of labor in the world, surgeons are going to be totally transformed by AI in the next decade. Right now, surgery’s way behind where it really should be in terms of where we are in terms of tech. So we’re somewhere between the, to use a driving analogy, the horse and buggy era and the car era now. There’s not really much autonomy happening at all, whereas for driving, of course, we have Tesla, Waymo, and others deployed autonomous cars on roads now. So we’re taking surgery to that point where it’s going to be mostly autonomous. Surgeons will still have a job and a role to play, but a lot of it’s going to be done by AI.

Alex Wilhelm: 2:34 So now you guys currently have a system that involves an, an iPad app, endoscopy so we have a camera that can look and see where we are. You work with surgeons, so it’s kind of surgeon-mediated. And there’s also a robotic arm doing some of the work. It might be better if you do to explain kind of what the current Andromeda system is and then what procedures it can kind of currently tackle.

Nick Damiano: 2:56 Yeah, so it is a robot that’s controlled by an iPad. The robot is fairly simple. It’s an arm… Off-the-shelf arm, we don’t want to be a company that builds lots of complex hardware, the exciting part is really in the software. And so what’s happening on the iPad is the important part.

Jason Calacanis: 3:11 Okay.

Nick Damiano: 3:12 We are starting with urology with this procedure called HoLEP, it’s for BPH or a large prostate, something that almost every man gets at some point in life. And then we’re expanding from there into other urology and then other, a lot of other surgical procedures to where this can be a general platform doing most types of surgery eventually.

Jason Calacanis: 3:31 If I was thinking about the realm of surgery, and you know, as a non-surgeon I’m clearly an expert, I don’t know if I would have gone with urology and endoscopy because it involves putting things in sensitive places, which to me seems a little bit terrifying. So just because I’m such a layperson here, why was this the right procedure to pick as kind of the company’s wedge point into our future more autonomous surgical future?

Nick Damiano: 3:53 Yeah, one of the things you wouldn’t expect in surgery is that urologists were the first adopters of robots and really one of the most tech-forward types of surgeons.

Jason Calacanis: 4:06 Really?

Nick Damiano: 4:08 Yeah. So like Intuitive with the da Vinci robot started in urology initially. Um, there are a lot of procedures though like this HoLEP procedure that are not done with robots now. So da Vinci covers some of it but then we’re covering basically everything else in urology. And we have these surgeons that love robots, that really want new tech to do these other procedures. And this HoLEP procedure specifically is one that’s really hard to do. And you’ve got this huge gap between somebody who’s just learning who takes like five hours and struggles through a procedure and then the best in the world who’s doing it in 30 minutes easily. And so we want to elevate everybody from the novice on up up to that level of the best surgeon who’s just cranking through eight or ten cases in a day with no problem.

Jason Calacanis: 4:47 This begs the question of what in the current system is autonomous, what is educational, and what is assistive? I’m trying to figure out kind of today what can Andromeda bring to a surgeon who hasn’t done a HoLEP procedure before to help get them from, ‘Oh god, this sounds scary’ to ‘I can do three or four or eight of these in a day’.

Nick Damiano: 5:06 So right now, you can do it robotically with the iPad. And so that’s like just kind of table stakes for a robot, you can do the procedure using our controls. And then we’ve built some early autonomy features. One is like Google Maps for the body where it tracks the landmarks and what you’ve done in the surgery so far in real time throughout the procedure so you always have that spatial sense and just know where you are and what you need to do next. And then there’s also, we built this auto-pivoting where instead of having to worry about all the degrees of freedom of the scope, it controls the pivot point and kind of auto-adapts to force. To minimize, as you can imagine in the area that urologists operate, you don’t want to have these huge forces applied where it’s going to cause all kinds of damage. And so we automatically minimize that, which we think will reduce the the incidence of things that… are damaging in that space. And then we’re releasing software every week, so we’re in the cadaver lab, we’re in the clinic doing live cases all the time, and then we’re building stuff and every week we release new features and are improving the autonomy level to where it’s becoming more and more autonomous and then easier and easier of course for the surgeon.

Jason Calacanis: 6:18 Yeah, to be clear, I was not trying to be rude by saying what autonomy exists yet. I think you’re laying the correct foundation, the right technology to get there. I’m just trying to figure out kind of like, as we draw this, you know, arc forward, where are we starting from? Because currently, as far as I can tell, there’s no autonomous surgery being done, so we’re, you have to build this. Now, data is an interesting question that I talk about with everyone in the broader AI space, and you know, scraping websites is not applied to you, nor does bringing in enterprise B2B workflow data. How do you get the information to train systems about human tissue and surgeries and such? Because I would presume there’s a lot less to, to scrape, so how do you get the right stuff to teach these robots to be more autonomous?

Nick Damiano: 7:02 The data is hard to get, that’s one of the things in this space that’s really challenging, and it becomes a moat for any company that operates in this space once you get that data. Um, you can get surgical videos from YouTube, and we’ve actually talked to a lot of surgeons that are YouTube creators that have shared some of their videos, so we have a huge data set of that type. But then there other things like the robot kinematics, the forces, anything else you can pick up in the procedure that is not available from just videos. So we have to get that data ourselves because no one’s ever collected that. So then being out in the clinic doing these cases is how we, we get it. Right now we’ve done, I think, the only, we’ve done 45 cases and it’s the only data set of 45 cases that exists. Like that’s 100% of the world’s data, and it’s really hard for anyone else to get that.

Jason Calacanis: 7:47 Yeah, so then as you want to add procedures, you know, moving away from just HoLEP and urology and endourology, I think is the phrase that I had to learn while prepping for our chat today. Um, how, are you going to have to go out and do that as well, or are there data sets that exist that you could bring to bear on bringing more autonomy to robotics, or is this going to be you guys have to create it every time you want to add collarbone surgery or whatever it is?

Nick Damiano: 8:12 So it is scalable in a few ways where we’re not just starting from zero. One, one thing is that you can break surgery down into a series of surgical tasks, and so once we can make tasks autonomous, those might be repeated in different procedures. And so that’s one way we’re going to be able to scale faster and faster as we build. And then we can also go back to the tactic of taking videos for different procedures. There’s people even building databases of surgical videos. So to at least get started we can access those or talk to the surgeons we, we work with, get videos and build some basic features based on that and then expand from, from there.

Jason Calacanis: 8:51 Is there a flywheel effect? Like as you get a bunch of data from other parts of the body, like if you get really good at working on livers, does that apply anywhere else, or is the body sufficiently specialized that what works for kidneys in terms of pressure or sensitivity or vision or whatever, just does not apply to I’m going to name another thing. A gallbladder.

Nick Damiano: 9:03 Yeah, because because the set of surgical tasks people do now is finite and pretty small, then yes, you can you can generalize across procedures. If you do a say a prostate enucleation versus an eye enucleation, there’s similarities to that. I mean, so in different parts of the body, you can repeat some of the stuff you’ve built. And that’s how we’re planning to to scale from maybe one or two new procedures a year now then up to four, five, hopefully 10 someday.

Jason Calacanis: 9:32 OK, so you have identified a real problem and you put together a solid solution and a business model that you believe in. So you’re all set to launch your new company, right? Uh, not so fast. If you want investors and potential customers to take your new business seriously, you need to consider forming a Delaware C Corp. And that’s where Northwest Registered Agent comes in. They’re going to give your new company a real identity. That means an address for your public filings, a domain, a custom website, a business email and, of course, a phone number. And that’s going to take just 10 minutes and 10 clicks. They don’t charge hidden fees. Customer service is available around the clock. They’re not overwhelming your inbox with spam and they make it easy to cancel at any time. So get all the advantages of a Delaware C Corp independent, regardless of where in the US you’re operating from. Visit northwestregisteredagent.com/twist for more details. And the links are in the show notes.

Alex Wilhelm: 10:26 You just mentioned that there’s kind of a finite number of surgeries that we do. That’s a very interesting point to me, because when I think about it, surgery does seem to be relatively broad. But it sounds like it’s actually more narrow and more systematized than I might have thought?

Nick Damiano: 10:39 It is. So there’s there’s a finite number of surgeries and it’s it’s the world in general is more bounded than, for example, driving. There are fewer edge cases. Not that there aren’t edge cases. Surgery is the body is more variable than you would would think. But it’s a lot less complex than the entire outside world that cars are operating in. The data is more scarce, so you don’t have as much training data to go on, but then the world is less complex and most importantly, you don’t have these other adversarial actors like other cars or pedestrians you have to model their behavior when you’re in surgery. There’s nobody else working against you, fortunately, when you’re in the human body.

Alex Wilhelm: 11:15 No, that makes a lot of sense. I mean, because the body can’t fight back because I presume everyone who’s getting surgery done in this way is unconscious, so they’re not even moving. They’re just, you know, pretty much static. No, I appreciate that. So when you decided to build the company, was it kind of made possible by the fact that there are now off-the-shelf robotic arms that are sufficiently finely controlled and workable that you could build this? Is that a new thing in the market?

Nick Damiano: 11:41 That is that is new. There’s there’s this arm from Kuka that we use right now, they’re a German company that makes robot arms for different use cases. And there weren’t that many until very recently you could use off the shelf. We could have possibly built one, though it would have been a lot more complexity for us to take on. How did we exist before this for people to really embrace this concept and one was surgical robots in general, mostly DaVinci from intuitive. And then autonomous driving because now people are accepting that cars can drive themselves with Waymo and Tesla and so on. So those two things coexisting make the world a lot more receptive to what we’re building now.

Jason Calacanis: 12:19 Why use off-the-shelf tools versus something that you designed for your own use? Now, I love the idea of getting to use whatever people have around loosely. But to me, it sounds like if you’re building something for a robot, it might have a different shape, a different sharpness than something that a human might use. I’m curious about that.

Nick Damiano: 12:41 I mean, there are great tools for surgery already and we want to focus on what we are, what we’re good at as a company, which is building this autonomy layer. And so we, while it does help to have a robot, to have some physical incarnation where you can actually control the whole autonomy loop, it doesn’t really help to build custom tools. So it’s a lot faster for us to be able to focus on the software and not have to build a tool for every surgery that’s done. Companies that choose that game, which is basically every other robotics company so far, that exists so far will find themselves moving a lot slower and a lot more inertia than what we have.

Jason Calacanis: 13:21 Yeah, you really kind of excised all the things that you don’t need to do in-house, focused on data collection software improvements through an iPad mediator. And that does seem to be a really fast way to build a better system. But that does kind of bring us into the what happens when it works and how doctors fit into this. Now, on one hand, every surgeon that I know is completely overloaded, exhausted, burnt out, and about to fall over. On the other hand, they’re quite highly paid and so there’s kind of a bit of a trade-off there. But to me, the idea of letting surgeons do more work more quickly, you know, with the help of autonomous tools makes a lot of sense. On your website, you guys talk about this being a super surgeon, which I really appreciate. That’s a good framing. But down the road in time, maybe not 10 years, maybe it’s 15, I can also see this technology improving to the point to which it can handle routine stuff like taking out my appendix if it’s going to explode, for example. And so how do doctors and surgeons feel about being accelerated and then possibly down the road made slightly archaic or anachronistic in certain procedures?

Nick Damiano: 14:16 I think like a lot of areas that AI is expanding into that the job of a surgeon will change fundamentally, but it’s not necessarily going to go away. I mean, there may be a point in the future that all of our jobs go away and it’s all just AI and we’ll have to learn to reckon with that when the time comes. But for this one, I think it’s going to be just a surgeon seeing their job in a different way than way before it becomes something that totally replaces surgeons. So what we envision in the long term is a surgeon sitting at kind of an air traffic control center where there’s a lot of different procedures happening. They can orchestrate that at a high level but not have to do all the tedious mundane tasks all the time. So maybe you’re overseeing 10 surgeries instead of one right now. And your job in each surgery is different, it’s more high-level and less just routine low-level stuff than it is now. And most surgeons we’ve found are really into that. The people, they want things to be autonomous. They want to have these unpleasant mundane tasks taken away up to the point that they’re totally cut out and don’t get paid anymore, and that’s a line we don’t really worry about crossing.

Jason Calacanis: 15:24 Well, I think we’re far enough away from that that that’s going to be a great problem to solve once we get there. But it does sound like as we’ve seen software development get automated to some degree by AI in a very condensed time period, this is going to be similar-ish but over a longer time period. For example, now a lot of developers orchestrate or observe and guide their agents versus writing the code themselves. This sounds analogous to that, although I do think it’s going to take a longer time to get the data we need to tackle more surgeries than it is to get more coding data which is indexable, available, and online. How could you guys go faster?

Nick Damiano: 15:58 That’s the question we ask ourselves every day. So we’re really besides, you know, the goal of the company to just get to this like big autonomous surgery vision, we’re really focused on being the fastest iterating company in the medical world. So we want to take the iteration cycle down from what it is now for most companies, it’s years, down to a month or weeks. And we’ve done that in the clinic so far. We’ve been basically doing cases, then building new stuff, testing on the bench, cadavers, then back into cases in less than a month. And it’s been shocking to the surgeons that have seen that there are way better features this month than there were last month. It’s not something…

Jason Calacanis: 16:42 That’s not the way the medical world has ever gone. That’s not MedTech. That’s the inverse of how medical technology has usually expanded. So of course they’re blown away. They’ve never been treated like a first-party customer before. They’ve always been treated as the thing that gets approved after the insurance company says yes. So yeah, I bet you’re popular.

Nick Damiano: 16:56 Yeah, and it’s really just focus and automation that are the key principles behind that when I talk about not making every device for surgery, like anything that goes into the patient, and just looking at every step of the process and asking ourselves, how can we make this faster? How can we automate parts of this? That’s the key. And I think most companies don’t do that. In MedTech especially, people just are not into automation. They’re following an old playbook that is usually quite slow and it’s really hard to scale.

Jason Calacanis: 17:24 Well, I mean, you could hit them like a hurricane then because they’re not even playing the same game. So that’s quite nice. Now going back to the car analogy, self-driving as kind of a thing we’ve figured out is going to help people get to understand this. One thing that self-driving companies do, and we’ve talked to Waabi and Wayve and everybody, they’re very interested in world models, and they have tinkered with synthetic data. And I’m just curious if those two things have any play in your realm or if those are things that don’t work quite as well inside of dense biological systems.

Nick Damiano: 17:53 You could describe it as a world model in a way. So I think that concept, and it’s there’s, I’ve seen a few different ways to define that concept. concept? I think that is basically what we’re building. In terms of synthetic data, we’re open-minded to that. We haven’t used it at all yet. There are definitely drawbacks to using that and there’s ways it could go wrong. And if we were to go down that route. So for now we’ve been using an approach that’s more, I guess more down the middle and not not using, not taking too many liberties in in that regard, though we will try things out and see if that’s something that produces good results as we move and, you know, make this more autonomous, go to more procedures and look for other ways to scale. Maybe synthetic data generation capabilities get better and better to where we do want to use those. And one thing we have to just like think about as we do this is that AI is advancing really fast and we want to be able to ride that wave and still stay up with whatever the latest capabilities are.

Jason Calacanis: 18:52 Literally stealing my next question. So, Nick, I’m curious about how advances in general AI technology is improving or aiding the company, because it seems like in the era of Fable, we’ve made a lot of progress since GPT-4.5. So, tell me.

Nick Damiano: 19:03 I mean, we use AI for a lot of our operations. We have to make sure that like with things like like with coding, that it doesn’t introduce non-deterministic bugs that that end up causing big problems. So we have to put a few guardrails on that and make sure that we’re not overusing it. Yeah, definitely for all the documentation processes that bog down companies usually, I mean AI is a core part of everything that we do in in that regard. So in every every process that we we have, we look to use something, some kind of LLM or some AI to improve the process. So it’s really been about optimization and then yeah, for all the paperwork, it’s just massive in terms of how much effort it saves.

Jason Calacanis: 19:42 I was I was more thinking about like as we consider the idea of a of a super surgeon, again using that phrase from the website, how much does a increase in generalized AI intelligence help you get to that point? Like are the models smart enough today to accomplish your goals or are you do you still hope for some step functions in generalized intelligence you can bring to bear on your specific problem set that will help you resolve, you know, other use cases more quickly?

Alex Wilhelm: 20:05 One of the themes we talk about over and over again on This Week in Startups is making sure you do your chores. I’m no expert on these things, I have some experience. Stephen Estes from CLA is an expert. Let’s talk about being cash efficient. Tell us about efficiency and what you see in the in the top-tier startups in your practice.

Nick Damiano: 20:26 We’re seeing kind of an interesting trend out there where companies aren’t needing to raise quite as much as they had in the past. You really have to be careful as a founder to only take on as much money as you really need. You’ve got to do the forecasting, you’ve got to do the modeling, and you’ve got to dial it in and get it right. Otherwise you’re going to end up either not raising enough capital to get to where you’re going and you’re going to have to go get venture debt or go back, have an extender to the round, or you’re going to give up too much of the company because you just didn’t recognize how much money you actually needed.

Alex Wilhelm: 20:55 Yeah, very important to get this stuff right, folks. And that’s really a bummer when startups…

Jason Calacanis: 21:00 I don’t do things in a button-up way always have a great partner, a good partner to have on this adventure while things change, my friend Stephen over at CLA. So, if you want a trusted advisor by your side who will navigate you through taxes, accounting, and everything in between, it’s time to take action. Visit claconnect.com/withyou. And don’t forget to drop a mention that your boy J-Cal sent you. That’s claconnect.com/withyou. Start today.

Nick Damiano: 21:28 I think it would it would in the future or that if you could have a better semantic understanding of what’s happening in surgery. I don’t think it’s quite there yet to be as reliable as we want. We have to be careful in the beginning to not have things that are going to hallucinate in weird ways. So we’re not using as much generative AI in the the first version of this product, though that is a thing that I think there’s huge potential as it gets better and better, especially with a surgeon in the loop where they can have control over what’s happening and prevent things from getting out of hand, that we can introduce that more and more. For now, though, it is more of the kinds of AI machine learning that’s being used for autonomous vehicles, has been used in, you know, Tesla and Waymo.

Jason Calacanis: 22:07 Okay. Now, uh, two questions more. One about capital, one about commercialization. So when I think about robotics, I think about catastrophic levels of expense, nothing but love for everyone building robots, it just takes a lot of money and time it seems. Uh, you guys are using off-the-shelf technology for the arms, so I presume that lowers your overall capital needs, but does the company have access to the funding that it needs, and how interested is the venture community in backing you?

Nick Damiano: 22:30 We, well, we’re about to announce a round that we raised recently that will, will come very soon, so stay tuned for, for more on that.

Jason Calacanis: 22:37 Do you want to give us a hint? Like, like is it tens of millions? Is it hundreds of millions?

Nick Damiano: 22:46 It’s tens.

Jason Calacanis: 22:47 There we go, it’s between zero and 99 million everybody, breaking news.

Nick Damiano: 22:51 Yeah, so, so we’ve, I mean, we’ve been both very capital and time efficient so far. We were the fastest robot from zero to launch in three years and we’ve only spent about 15 million total in getting there, whereas the norm is hundreds of millions. And that’s because we don’t go crazy on hardware, we’ve moved fast, time is really expensive, and just automating as much as possible, that we don’t have to do all these manual tasks that add up to a lot of expense normally.

Jason Calacanis: 23:12 No, that’s, that makes a lot of sense to me. And now in terms of making quick software iterations, I presume that means you have a relatively advanced fleet of, of developers. Are there any like medical specific people you have to bring into the company to make this function? And if so, what, who are you hiring from the health world and bringing them into technology?

Nick Damiano: 23:30 One thing unique about us versus other companies that are in the medical space is a lot of the team or more than half of the team is not, has never worked in healthcare at all. And a lot of them came from spaces like autonomous vehicles. My co-founder built the first autonomous truck that ever drove on a freeway before this, and we’ve hired a lot of his former employees to this company now. We do have, we have looked at companies like Neuralink to hire some of the people that have more medical experience, we found that’s a company that really aligns well… terms of of culture with us. Um so it’s a much more deep tech and very unconventional team compared to what you’d see at like Intuitive.

Jason Calacanis: 24:08 What if, what if, what if, hear me out, we use the Andromeda surgical stack to do BCI insertion on mass? I think that would rock…

Nick Damiano: 24:17 A lot going for that now but it could could be a thing.

Jason Calacanis: 24:20 Well, after you get done fixing my prostate, can you just fix my brain? Like, I don’t know, man. Like, I that’s a that’s what I would do next if I was you because that’s super exciting and people would also just rain capital down on you. Okay, I’m kidding. Uh, in terms of commercialization, you mentioned you’ve done several dozen procedures. Uh, how many do you think you’ll have done by the end of the year? And when does this become something that you can do domestically with whatever the proper clearance is to or actually charge for it in a non-academic or research uh way?

Nick Damiano: 24:51 We have a lot of LOIs signed with people that are ready to pay for it once we’re able to deploy it. Of course, we are subject to regulations and we’re only cleared to be on the market in New Zealand right now, though we’re close in a few other countries uh as well. And so, so yeah, we are we are at the point that we’re ready to to launch the product.

Jason Calacanis: 25:13 Is the regulatory environment in the United States conducive to this technology being allowed to function or are we behind the curve a bit in terms of how uh welcoming we are to robotics automation in the realm of surgery?

Nick Damiano: 25:26 There’s nothing really that prevents this from being deployed. I mean, the same risk principles apply for this as they do for any product that’s FDA regulated. And so as long as we set up our risk analysis, our quality system the right way, then nothing prevents this from happening. The fact that surgeons are in the loop really helps that I think if you’re going to deploy something that’s totally autonomous that you press a button and then walk out of the room, that would be a lot more challenging. We need to take this in the right steps, though. One thing with FDA is that what really matters is the increment over either what they’ve seen before or what you last submitted. So we want to make those increments really like relatively small but then also come back frequently with new updates so that every little bite they have to take is is not that big and then eventually that adds up to autonomous surgery across a huge range of procedures.

Jason Calacanis: 26:12 Huge range of procedures. And I also kind to wrap up here, I’m curious about a huge swath of the world because, you know, one thing that I’m really hopeful when it comes to companies that are working in the medical technology space and are making things faster, cheaper, easier and so forth, is that they’re going to be able to take these technologies around the world to places that don’t have access to kind of already modern healthcare and empower doctors to do a lot more. So is there a future when like there’s your setup in a clinic somewhere and maybe like a doctor can like remote in to it from a place where they’re qualified and trained in and allow them to do a lot of surgeries, maybe via Starlink, uh where they couldn’t normally get to and these people wouldn’t have access to it?

Nick Damiano: 26:49 Definitely. That’s one of the things I think is the most exciting about the long-term potential of this is that anywhere you want to be delivering healthcare, any facility around the world, even on other planets eventually… then you could have this in the operating room and it’s not that expensive in terms of the value that it provides and this could be the hub for all surgery in that center so whether it’s here at UCSF or in some remote village in a poor country then we could have you could have this installed there and then do any procedure with any surgeon anywhere overseeing it and so you give everybody access to the best possible healthcare like I mentioned earlier there’s this huge gap between one surgeon and the next in surgical skill so we could totally condense that so everybody gets the best surgeon in the world every time

Jason Calacanis: 27:42 Oh I see that gives me so much optimism for the future I feel like when we think about AI and autonomy everyone’s so focused on losing their job that involves clicking buttons when in reality the best and most important story is we’re going to make people’s lives quite a lot better Nick thanks for coming on where can people find the company online and is there a job that you’re looking to hire that you’d love to shout out into our audience

Nick Damiano: 28:00 Yeah our website andromeda-surgical.com we’re on LinkedIn and X and other platforms and we are hiring so we have a lot of technical roles open both software hardware robotic controls and then looking for people in like launching the product and clinical as well so definitely hiring looking for people that have this ambitious mindset to build something that could be really define the future of surgery and so anybody who wants to take on a really hard project that could have big impact then reach out

Jason Calacanis: 28:34 All right well Nick I’d love to when this is approved for use in the United States I can’t wait to see how quickly it expands thanks for coming on the show we’ll talk to you in six or nine months

Nick Damiano: 28:41 Thanks Alex thanks for having me

Jason Calacanis: 28:43 All right everybody next up on today’s twist we’re going to talk about a really big trend which is tokenization and syndicates we’ve been talking about tokenization for a decade it’s incredibly annoying to talk to crypto people and fractional ownership and blockchain and it’s immutable and none of this has ever really worked and it’s a big question mark ten plus years later then on the other side you have syndicates something that’s worked incredibly well AngelList pioneered them we got involved with thesyndicate.com creating an SPV allowing a group of people to act as one unit to buy an asset well today on the program we have Alex Blackwood he is the founder and CEO of Mogul M-O-G-U-L and what he’s doing is he’s saying

Alex Blackwood: 29:24 hey people want to buy into single-family rental properties right if you are an investor and you’ve got a portfolio you want to maybe build some rental there’s plenty of reasons to do that and we’ll hear about that today but you are maybe you buy one or two of these units as an affluent person and then you’ve got a number of issues you’re only you’re not diversified etc so what if more people could invest and they could invest as little as 250 dollars

Jason Calacanis: 30:00 dollars. Similar to with our syndicate that invests in startups, our minimum on most deals is 5k or 10k. Most of the time when you invest in a startup, the minimum is 50k to 250k for a company to take you seriously. And if you get to Series A or B, you know, they’re probably looking for seven figures. Welcome to the program, Alex.

Alex Blackwood: 30:21 Thanks so much for having me, really appreciate being on.

Jason Calacanis: 30:23 The founders I’m talking to are shipping code faster than ever thanks to AI. But one big important question remains: if every feature you write and ship has to slow down for an overwhelmed database, what’s the point? But fear not, the solution is MongoDB. Instead of wrestling with rigid schemas and painfully reworking antiquated data structures and formats, MongoDB’s native data model perfectly mirrors the language LLMs are already speaking. MongoDB gives you the flexibility to ship at the speed of AI. The ACID compliance guarantees you actually get to sleep at night while it scales to handle massive Fortune 500 workloads. And the best part is, developers swear by it. Literally. I can’t use the actual words they said in this ad, so let’s just call it a really great database. Start building at mongodb.com/ai. And so tell us a little bit about what you’re building, and like how many homes have you put on the system? How many investors typically go into a home? Take us through the numbers.

Alex Blackwood: 31:21 Yeah, of course. And so you hit the nail on the head, right? The idea is buying shares in a single-family rental home. So myself and co-founder were both at Goldman Sachs in their real estate private equity group where my co-founder grew Goldman’s single-family rental platform from zero to a billion in under 12 months with three to four individuals. So we took that approach of diligence, of vetting, structuring the deals, and actually gave access to everyone to invest. And so when you’re buying into a single-family rental home, it’s fully vetted, fully diligenced on our platform, fully structured, and as a result, you get all the direct benefits of it, including dividends from rental income on a monthly basis, appreciation, we track it in real time, and then tax benefits at year-end. And so the idea behind it is as for the numbers, we’ve done 130 properties and within those properties we have about 600 plus units as we see on the site there. And these properties typically range anywhere from 500k all the way up to two and a half million dollars we’ve done. Typically when you’re investing, yes, it’s a 250 dollar minimum, however, people on average are investing 15, 20k plus into these deals. So you’re typically looking at anywhere from 20 to 80 investors per deal on average.

Jason Calacanis: 32:41 Got it. And so when we look at one of these homes, you know, they tend to be 250k, 500k. And so if I were to put in 5k, I’m 1%, I’m a 1% owner. But managing these is incredibly hard. So walk us through that piece of the puzzle. How does that work? Who manages it, who makes sure that it’s generating revenue and how do you not get upside down and have to go to your investors and say, ‘Hey, this thing’s not renting, hey there was a flood, hey we’ve got an insurance payment.’ You know, we don’t have to deal with those issues when we’re doing a startup SPV. We do have to deal with legal, K-1s every year, so we have our own set of issues that we might have to manage. But we certainly don’t have to manage somebody like tearing the place down or a flood. So walk us through the management of each property.

Alex Blackwood: 33:30 Yeah, I mean, so that’s part of the value add for the end investors. It’s completely headache-free. And so real estate, as we know, is the world’s largest wealth generator. There’s that old quote from Carnegie: 90% of millionaires became such through real estate investing. However, the headaches attributed to real estate are tremendous, right? You’ve all heard the horror stories of the 3:00 a.m. tenant coming to you because the sink is burst. Now, with us, we work with direct boots-on-the-ground property managers to actually operate this property. And so they do a few different things for us. If you walk from kind of top-line down to bottom-line, on the top-line from the revenue side, they’re the ones making sure these things are rented out appropriately. We do algorithmic pricing to make sure that they’re attractive across Airbnb, PadSplit, and on the long-term rental side, to make sure that we’re optimizing for revenue—really dynamic pricing there. Then all the way walking it down to the bottom line, we deal with the utilities, we deal with the property manager who is working with any—any tenant that might have an issue or any sink that might burst. Now, for you as an end investor, anything below $1,000, the property manager takes care of it. You don’t have to deal with it at all. Anything above $1,000, it actually triggers a governance vote. And so the idea being, saying, listen, sink burst, $100, you don’t deal with it. HVAC burst, $6, $7K, we’ve got these two quotes for you, we recommend this quote, or we can get a third option, you come in, you vote, and also you can kind of assign the vote to the property manager to decide. Now, as for the actual kind of management on the go-forward and all of that, you are really hands-off as it relates to the property itself. So that’s kind of the way that it works. Oh, and as for the capitalization, right? And so thinking about mitigating against that major CapEx burden, so that HVAC burst at 7K, we actually don’t ask for any additional dollars from the end investor. As part of each individual raise, we capitalize a maintenance and a vacancy reserve. Maintenance reserve, we basically take into account the inventory of a home, say, okay, the HVAC is on year six of ten. We know that in the next five to seven years, we most likely will have to buy a new HVAC system. As a result, we capitalize that adequately enough in the maintenance reserve and then… Vacancy reserve, we actually capitalize a 12-month reserve, so that asset could sit completely vacant for up to 12 months and we would never call another dollar in the door.

Jason Calacanis: 36:10 So what is—what is the goal of your investors? They want to get 10, 15% back every year in a dividend or they want to get the appreciation and they’re pushing you to sell this in five years and flip it? What’s the goal of the investors, and how do you communicate that to them? Because they’re two separate goals, yeah?

Alex Blackwood: 36:28 Yeah, so on the platform itself, we like to say that we give as much, if not more, information than we would have needed during our time at Goldman’s investment committee to make a decision on that asset in a much more digestible format. So the assets range from a mix of higher on the rental income and less on the appreciation, maybe they’re a little bit more stable on cash flow; maybe they’re more on the appreciation, less on the cash flow. All things told, the assets typically yield between 8 to 12% per year for dividend payout. That’s dollars that you can withdraw tomorrow, if you so choose. And so when you do that, that’s the dividend payout, it’s paid out monthly to you, you can withdraw it at any time. The appreciation, too, obviously it’s around 3 to 4%, but because we lever up each purchase, we buy it with a mortgage in place, it actually results to another 4 to 8% on top of it. So all things told, it’s between 15 to 20% typically. We underwrite to a 12% IRR on bear case scenarios to make sure it’s completely conservative. We convey that to the end investor, so as you can see on the site, everything is completely forthright as transparent as possible. You know exactly what you’re getting into. And the last piece that we always love to talk about, we like to joke that the IRS wrote the tax code to incentivize two things: procreation and homeownership. We can’t help with the first, but we sure as hell can help with that second. And these assets typically, even though you’re getting 8 to 12% in rental income, it actually is a passive loss for income reporting purposes, so no taxes on it.

Jason Calacanis: 38:01 Wow. To explain that—understand—I’m not like Donald Trump or like these real estate moguls, I know the whole system is rigged for real estate people. What does it mean in terms of the tax break that it’s losing money?

Alex Blackwood: 38:13 Even though the asset is appreciating in value, the structural component of the asset is depreciating, right? Obviously wear and tear throughout the property. So as a result, the IRS basically came up with this incentive program called depreciation. And so even though—it’s considered a ghost expense, meaning it’s not going to directly impact your cash flow, however, you can basically take that asset’s value, divide it up over a set number of periods and put that up against any rental income that you might receive from the property. And so it’s almost a deduction after the fact. So even though you’re generating that 8 to 12% yield, the depreciation should cover it up and then some, not to mention any other amortized major capital expenditure, so any other additional improvement that was done to the property.

Jason Calacanis: 39:00 How do you make money?

Alex Blackwood: 39:01 How do we at Mogul make money you’re saying? So, we charge a platform fee upfront, it’s 5%, charged as percentage of purchase price. Amortized, you can think of it as a similar drag on return as a 2 and 20 structure of any alternative asset manager. It actually is less so because that 5% over a five-year period, 1% per year, obviously it’s upfront, and time value of money on the return is something else. There are other two revenue streams that we have in addition to it. One is we’re starting to really enact on our product roadmap and become all things up and down the supply pipeline of real estate. We’re actually a lot of times not working with a broker on the buy side, and so as a result, we have an additional one and a half percent that is paid to us by the seller at closing. Does not impact an investor’s, but just an incentive for us to keep these properties coming. So, the first revenue stream, 5% upfront on the purchase price, that is incurred by the customer. The 2% or one and a half to 2% is incurred by the seller, so does not incur anything to our customer. And the last one is interest on reserves. So, those maintenance and vacancy reserves, as a result we do scrape interest on those. Typically, it’s about a 2.75 effective rate there and, yeah.

Jason Calacanis: 40:25 So say you had a $100 million portfolio, and I think you might. If you had a $100 million portfolio that you’ve got people to invest in, you get that 5%, you make $5 million, and then you’d have that one and a half percent that you got as a kickback for being the the buyer and that’s paid by the seller of the home. So you’re sitting on $6.5 million. It’s not anything to write home about, uh, but it’s not nothing. You are essentially getting paid that fee. It’s a decent fee. Um, and then you have all these other services where you can make a little money. So that nets up if from what I’m understanding or it feels like that maybe you can make 10% over the five years on the life of the home. Am I ballpark correct?

Alex Blackwood: 40:58 Yeah, so we’re actually entering into additional revenue streams as we speak. So it’ll actually be north of that. And the idea being we have a title insurance joint venture that’s starting by end of the quarter here. That’ll add an additional call it nine, 10, 12k per asset, which is going to be incredible. And then we also are going into other verticals like property insurance. In year one, premiums from that property, we can underwrite the property better, we have better sources of data for the property, and as a result of it, we can lower the property insurance, increase cash flow to our end investors, all while generating roughly four to five million dollars in recurring revenue year one.

Jason Calacanis: 41:38 So if somebody gets divorced or somebody passes away and they have an inheritance, they’ve got to get out of this. They’re in year one, they invested $50,000 with you, it’s year two now. How can they get their money out? Is there a marketplace to sell it? Can you buy it back for them at a discount or something? How do you deal with redemption—early redemptions—because we have this… You know, in startup land, we’ll get a notification from somebody, ‘Hey, I’m getting divorced. I put a quarter million dollars into startups, and we have to figure out how to put two people on the cap table,’ or they’ll ask us, ‘Hey, will you buy it back from me, 20 cents on the dollar?’ and we’re like, ‘Well, we really don’t have the ability to do that.’ Sometimes I look at it as the GP and I’m like, ‘Maybe I’ll buy it from you,’ but it’s just it’s kind of a hard situation. So how do you deal with the early redemption issue, if at all?

Alex Blackwood: 42:26 So there are two prongs to that. Number one today, it’s a five to seven-year typical holding period, and we’re very transparent with the end investor, and they think of this as a very high-yielding savings account almost with a high appreciation on the back end. So five to seven years up front. Now, the idea is we are launching a secondary market target of next year, and with that secondary market, we’re looking to do what’s never been done before, which is a fully liquid secondary market. So I worked with market makers during my time at GS in their investment banking division, got a chance to see how they do it firsthand, was amazed at just how efficient these markets are. Typically when you think of the New York Stock Exchange and you’re buying into and out of, let’s say Tesla, you might sell out of Tesla, and the person on the other end of the transaction isn’t actually a person at all, it’s an institution. That institution is buying it, repackaging it, maybe selling as part of an S&P 500 ETF or maybe just selling it to another individual investor. They’re bearing that what’s called overnight risk. So as a result, day one, we’re actually going to come in and work as that market maker. And so the idea being maybe we get some sort of bid-ask spread in there, like a little bit of a scrape on there, and the idea being that if you want to sell, you could sell out tomorrow. We come in, we provide you liquidity, we get a minor bid-ask spread, and because we are generating rental income that yields between 8 to 12 percent in a year, that would actually cover any debt service that we have to actually liquidate out that asset for the end investor. So as a result, day one we will act as market maker, but day two is really where it gets interesting with a number of different products, different risk-reward profiles to make it truly liquid.

Jason Calacanis: 44:11 How do you pick where to buy the homes? Uh, this is like a very dynamic market. You know, in Austin we have people, they don’t seem to stop building. They just build, build, build. You want to build something, they’re just like yolo, go for it. Houston same thing. Sure land, build what you want. And rents and home prices have gone down for four years in a row, I think, which is awesome for my team members. And when you start a company here, I highly recommend everybody move to Austin. Your staff will love you, your team members will love you because their rent will go down two-thirds if you’re living in a major city, or you’ll be able to buy your first home because first homes here are 250k to a million dollars, just 30 minutes outside the city. So it’s a pretty great deal. How do you think about where to buy and what to buy?

Alex Blackwood: 44:56 Yeah, so we come up with the initial market thesis, right? Saying net new supply on the horizon is not enough to meet demand, so For instance, in Austin, you did have a run-up in supply that happened from 2020 to 2022 in that range and then prices plummeted by about 25%. But the net new demand on the horizon for Austin is looking incredibly attractive, especially given the fact that a lot of developers are scared out of that area. So that’s exactly kind of the thought process behind it is: is that supply on the horizon enough to meet demand? Is the rent as percentage of price a high enough dislocation to generate an attractive yield to our end investors? So is the market thesis there? Is the operating model there? And then, do these assets operate within our typical target price range? From there we come up with that initial market thesis, we go into it, we find infrastructure players, we incentivize them, and an outbound motion that starts at day one becomes an inbound motion where assets are coming to us meeting our buybox criteria and then we cycle through the full diligence process around it.

Jason Calacanis: 45:58 All right, if you want to get more information go to mogul.club. Really interesting startup. I’m fascinated by it. I’m fascinated by any group of syndicates buying assets together and scaling that, and we wish you great success.

Alex Blackwood: 46:13 Thanks so much, appreciate it, Jason.